GSTM1 and Neurodevelopmental delay: The pooled results showed that for both NDD patients (Figure 3A) and DD patients (Figure 3B), △Hb levels were significantly higher in the daprodustat group than that in placebo cohort (MD = 1.73, [95% CI, 0.34 to 3.12], p = 0.01; MD = 1.88, [95% CI, 0.68 to 3.09], p = 0.002; respectively), but there was no significant difference between daprodustat and rhEPO in terms of changes in Hb levels (MD = 0.05, [95% CI, −0.49 to 0.59], p = 0.86; MD = 0.12, [95% CI, −0.28 to 0.52], p = 0.55; respectively).